DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Author: George Shand, Final Year Medical Student, University of Auckland, New Zealand; Chief Editor: Dr Amanda Oakley, Dermatologist, Hamilton, New Zealand, August 2015.
Afamelanotide (SCENESSE®, Clinuvel Pharmaceuticals) is a potent alpha-melanocyte-stimulating hormone (αMSH) analogue, which stimulates the production of eumelanin in the skin — a tan, induces antioxidant activities, enhances DNA repair processes, and modulates inflammation. This injectable synthetic melanotropic peptide was previously known as Melanotan I.
Eumelanin is a form of melanin, the tanning pigment in the skin. Production of melanin is usually stimulated by exposure to the ultraviolet (UV) radiation component of sunlight.
Afamelanotide is registered to treat erythropoietic protoporphyria. It has been reported to be of benefit to patients with:
Erythropoietic protoporphyria (EPP) is a rare, inherited disorder of metabolism typically manifesting in early childhood as painful photosensitivity. One to 20 minutes after sun exposure, patients experience burning pain on exposed skin, usually hands and face, followed by swelling and redness that lasts for several days. The fear of this pain can have a major effect on quality of life including work and recreational opportunities.
Afamelanotide has been shown through Phase III studies to decrease phototoxic reactions and recovery time in patients with erythropoietic protoporphyria. Afamelanotide was approved for treatment of erythropoietic protoporphyria by the European Medicines Agency (EMA) in 2016 and by the FDA in the US in October 2019. It reduces pain and allows nearly all patients to be outdoors for longer periods than previously. However it has no effect on the number or duration of phototoxic reactions. Quality of life is significantly improved. Sunlight avoidance and wearing protective clothing remains essential; afamelanotide is not a cure for EPP.
Solar urticaria is a rare form of chronic physical or inducible urticaria characterized by itch, weal and flare within minutes of sunlight exposure. The action spectrum (the part of the electromagnetic spectrum that causes symptoms) is variable, but most often involves long wavelength UVA and visible light. The use of afamelanotide has been shown under experimental conditions to reduce weal formation secondary to increased melanisation.
Vitiligo is a disorder characterised by white patches of skin due to selective loss of epidermal melanocytes. UVB phototherapy is a cornerstone of vitiligo management; however repigmentation has been shown to be faster and superior when phototherapy is used in conjunction with afamelanotide.
Afamelanotide was prescribed to 2 patients with Hailey-Hailey disease (benign familial pemphigus) resulting in remission.
The use of afamelanotide has been associated with a 50% decrease in epidermal sunburn cells, as well as a significant reduction in thymine dimer formation (part of the process by which UVB damages DNA). However, the marketers of afamelanotide do not recommend its use as a sunscreen or treatment of sunburn.
Because no data is available, contraindications to afamelanotides include:
Afamelanotide (Scenesse®) comes as a white rod approximately 1.7 cm in length and 1.5 mm in diameter. It contains 16 mg of afamelanotide and is implanted under the skin, usually around the hip. It should be inserted by a specialist physician every 2 months, prior to and during increased sunlight exposure (eg, summer). It is recommend to have three implants per year, with a maximum of four per year.
The patient is asked to wait for 30 minutes in case of allergic reaction to it.
Tests before starting afamelanotide may include:
Regular full-body skin examinations are recommended prior to and every six months during treatment to assess and monitor pigmented lesions and other skin abnormalities, especially in those with a personal history of skin cancer.
Few major side effects have been reported thus far.
There is no evidence that afamelanotide increases the risk of melanoma. The primary risk factor for melanoma is UVB irradiation. Eumelanin production reduces UVB skin penetration and scavenges free radicals, hence protecting the skin.
Due to the method of administration, patients taking blood thinning medication may experience bruising or bleeding at the site of implantation.
No specific drug interactions have been identified to date (2015).
See the DermNet NZ bookstore
© 2021 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.